|1.||Prendergast, George C: 2 articles (09/2014 - 06/2009)|
|2.||Muller, Alexander J: 2 articles (09/2014 - 06/2009)|
|3.||Mandik-Nayak, Laura: 2 articles (09/2014 - 06/2009)|
|4.||Pigott, Elizabeth: 2 articles (09/2014 - 06/2009)|
|5.||Takikawa, Osamu: 2 articles (08/2014 - 11/2009)|
|6.||Ino, Kazuhiko: 2 articles (08/2014 - 11/2009)|
|7.||Löb, Stefan: 2 articles (01/2009 - 11/2008)|
|8.||Königsrainer, Alfred: 2 articles (01/2009 - 11/2008)|
|9.||Gilmour, Susan: 1 article (09/2014)|
|10.||DuHadaway, James B: 1 article (09/2014)|
05/15/2011 - "Thus, a specific inhibitor of IDO, 1-methyl-tryptophan (1-MT), is being used more and more frequently in anti-tumor studies. "
11/01/2008 - "Subsequent studies analysing IDO as an immune-regulatory enzyme describe its implications in cancer immune escape, as chemical abrogation of enzyme activity with 1-methyl-tryptophan (1-MT), results in enhanced antitumor responses in animal models. "
03/15/2011 - "Second, the apparent selective inhibition of IDO2 by the D stereoisomer of the IDO blocker 1-methyl-tryptophan (1MT), which tends to be more active than the L-isomer in a variety of biological assays for IDO function, suggests that IDO2 may be important to sustain immune escape and growth of tumors. "
01/01/2009 - "A novel therapeutic approach in cancer envisages inhibition of IDO with 1-methyl-tryptophan (1MT). "
12/01/2008 - "No synergism between IFNgamma-NGR and 1-methyl-tryptophan was observed in vitro in tumor cell proliferation assays or in nu/nu tumor-bearing mice, suggesting that the antitumor effect was host mediated. "
06/01/2010 - "This study examined whether 1-methyl-tryptophan [1-MT, an indoleamine 2, 3-dioxygenase (IDO) inhibitor] could reduce CD4+CD25+ regulatory T cells (Tregs) proliferation and improve the anti-tumor efficacy of dendritic cells (DCs) pulsed with tumor cell lysate in the mice bearing pancreatic adenocarcinoma. "
|5.||Melanoma (Melanoma, Malignant)
03/01/2014 - "In melanoma and lymphoma tumor models, MSC-IDO promoted tumor growth in vivo, an effect that was reversed by the IDO inhibitor 1-methyl-tryptophan. "
12/01/2008 - "Coadministration of 1-methyl-tryptophan, an inhibitor of IDO, increased tumor responses to multiple treatments in the lymphoma, melanoma, and fibrosarcoma models. "
10/01/2013 - "Here, in a scenario involving the tryptophan catabolism, we report that melatonin biosynthesis is driven by 1-methyl-tryptophan (1-MT), a competitive inhibitor of IDO1, in human fibroblasts, melanocytes and melanoma cells. "
|1.||Interferon-gamma (Interferon, gamma)
|2.||Transforming Growth Factors (Transforming Growth Factor)